Pembrolizumab in HER2-Positive Gastric Cancer
- Study type
- Other
- Design
- Scientific letter (Correspondence) published in NEJM; listed in the PubMed record as a comment on a 2021 paper in Nature. No abstract is available in the record.
- Source
- N Engl J Med · 2024
In plain words
This paper is a short scientific letter about using the drug pembrolizumab (an immunotherapy drug) in HER2-positive stomach cancer. The available record has no abstract or results, so no conclusion about how well the drug works or its side effects can be drawn from it. To find out whether this medicine is right for you, talk to your treating doctor.
Study population
The PubMed record has no abstract; no information on the study population is available. Details in the full text of the paper.
Endpoints
The PubMed record has no abstract; endpoints are not stated in it. Details in the full text of the paper.
Safety and side effects
No safety information is available in the PubMed record. Details in the full text of the paper.
Clinical significance and place in guidelines
The PubMed record has no abstract and the clinical impact of this letter cannot be derived from it. To determine its place in the treatment of HER2-positive gastric cancer, the full text of the paper and current clinical guidelines should be reviewed.
Limitations
This card was prepared only from the bibliographic information of the PubMed record. The abstract, study design, number of patients, doses and results are not in the record and should be completed from the full text of the paper (PMC11620791).
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.